Genmab A/S (NASDAQ:GMAB) Research Coverage Started at Cowen

Cowen took over coverage of shares from Genmab A/S (NASDAQ:GMAB – Get Rating) in a report published Monday, Briefing.com reports. The company assigned a market perform rating and a price target of $38.00 on the stock. Cowen’s price target indicates a potential upside of 8.02% from the company’s current price.

Several other analysts have also recently issued reports on the stock. JPMorgan Chase & Co. lowered its target price on Genmab A/S shares to 3,100.00 from 3,200.00 in a research report on Friday, February 25. Cowen began coverage of Genmab A/S shares in a research report on Monday. They gave the company a “Market Perform” rating. Guggenheim downgraded Genmab A/S from a “buy” rating to a “neutral” rating in a research report on Monday, January 3rd. HC Wainwright reiterated a buy rating and price target of $47.00 on shares of Genmab A/S in a report on Thursday, March 17th. Finally, SVB Leerink lowered its price target on Genmab A/S to $39.00 from $42.00 and issued a research note on Thursday, February 17th, stating a “market perform” rating for the company. Four equities research analysts have rated the stock with a sell rating, five have given a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $425.50.

GMAB stock opened at $35.18 on Monday. The company has a 50-day simple moving average of $35.11 and a 200-day simple moving average of $37.47. The company has a market cap of $23.13 billion, a P/E of 48.19, a price-to-earnings-to-growth ratio of 1.62 and a beta of 1.04. Genmab A/S has a 1 year low of $30.08 and a 1 year high of $49.07.

Genmab A/S (NASDAQ:GMAB – Get Rating) last released its earnings results on Wednesday, February 16th. The company reported $0.17 per share for the quarter, beating the Zacks consensus estimate of $0.13 by $0.04. The company had revenue of $402.74 million for the quarter, compared to the consensus estimate of $387.16 million. Genmab A/S had a return on equity of 14.23% and a net margin of 35.58%. Equity analysts are forecasting that Genmab A/S will report earnings per share of 0.76 for the current fiscal year.

Several major investors have recently bought and sold shares in GMAB. SG Americas Securities LLC increased its stake in Genmab A/S by 9.3% in the first quarter. SG Americas Securities LLC now owns 6,050 shares of the company, valued at $219,000, after purchasing an additional 513 shares last quarter. Comerica Bank increased its stake in Genmab A/S by 3.8% in the first quarter. Comerica Bank now owns 17,313 shares of the company’s stock, valued at $658,000, after purchasing an additional 636 shares last quarter. Ellevest Inc. increased its position in shares of Genmab A/S by 21.1% in the first quarter. Ellevest Inc. now owns 7,516 shares of the company’s stock valued at $272,000 after purchasing an additional 1,311 shares last quarter. Cim LLC increased its stake in Genmab A/S by 1.7% in the first quarter. Cim LLC now owns 27,994 shares of the company’s stock valued at $1,002,000 after purchasing an additional 465 shares last quarter. Finally, Veriti Management LLC increased its stake in Genmab A/S by 44.7% in the first quarter. Veriti Management LLC now owns 10,054 shares of the company’s stock valued at $364,000 after purchasing an additional 3,104 shares last quarter. 5.92% of the shares are currently owned by institutional investors and hedge funds.

About Genmab A/S (get rating)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases, mainly in Denmark. The company commercializes DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab, used to treat thyroid eye disorders; Ofatumurnab, a human monoclonal antibody used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Continue reading

Analyst Recommendations for Genmab A/S (NASDAQ:GMAB)

Receive daily news and reviews for Genmab A/S – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Genmab A/S and related companies with MarketBeat.com’s FREE daily email newsletter.

مقالات ذات صلة

زر الذهاب إلى الأعلى